نتائج البحث - "Vadim A. Doronin"

1

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

المؤلفون: Lionel Adès, Larisa Girshova, Vadim A. Doronin, María Díez-Campelo, David Valcárcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Sharon Friedlander, Douglas V. Faller, Mikkael A. Sekeres

المساهمون: Institut Català de la Salut, [Adès L] INSERM U944, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint Louis and University of Paris, Paris, France. [Girshova L] Federal Almazov North-West Medical Research Centre, Saint-Petersburg, Russia. [Doronin VA] City Clinical Hospital 40, Moscow, Russia. [Díez-Campelo M] Institute for Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, Salamanca, Spain. [Valcárcel D] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d'Hematologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Kambhampati S] Sarah Cannon at Research Medical Center, Kansas City, MO, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::antimetabolitos::antimetabolitos antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS], Antimetabolites, Antineoplastic, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Antimetabolites::Antimetabolites, Antineoplastic [CHEMICALS AND DRUGS], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Leukemia, Myelomonocytic, Chronic, neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mielomonocítica crónica [ENFERMEDADES], Cyclopentanes, Hematology, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores], Quimioteràpia combinada, Medicaments antineoplàstics - Efectes secundaris, Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myelomonocytic, Chronic [DISEASES], Pyrimidines, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Leucèmia mieloide aguda - Tractament, Other subheadings::Other subheadings::/adverse effects [Other subheadings], Azacitidine, Humans, Drug Therapy, Combination

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8838e72608b49d5e2a82c322c09cf86
https://doi.org/10.1182/bloodadvances.2022007334

Full Text via ClinicalKey

2

Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes

المؤلفون: Agostino Cortelezzi, Ivo Nnane, Guillermo Garcia-Manero, Mariëlle Beckers, Vadim A Doronin, Brayan Merchan, María Díez-Campelo, Helen Varsos, Nikki A. Deangelis, Matteo G. Della Porta, Koen Van Eygen, Liang Xiu, Dimitri Breems, Esther Rose, Edo Vellenga, Valle Gomez, Meagan A. Jacoby

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Stem Cell Aging Leukemia and Lymphoma (SALL)

المصدر: American Journal of Hematology, 96(4), E111-E114. Wiley

مصطلحات موضوعية: medicine.medical_specialty, business.industry, Internal medicine, Myelodysplastic syndromes, Transfusion dependence, MEDLINE, Medicine, Daratumumab, Hematology, business, medicine.disease

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1980eea6ad28973e30ed9207097e167
https://hdl.handle.net/11370/29d11ec0-2ba1-4d5d-83b2-82bdc660fdad

View record at Wiley

3

Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial

المصدر: Blood
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f5721a519b6f1e60c6aafec14ec22139
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16620

4

Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone

المصدر: Blood. 136:39-41

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::30deca5ba5a04dab36b59b452fb9b7d3
https://doi.org/10.1182/blood-2020-141319

5

Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study

المصدر: Blood. 136:48-50

مصطلحات موضوعية: Prior treatment, Oncology, medicine.medical_specialty, Bortezomib, business.industry, Immunology, Once weekly, Refractory Multiple Myeloma, Subgroup analysis, Cell Biology, Hematology, Biochemistry, Proteasome, Internal medicine, medicine, business, Dexamethasone, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::92b852e8d6b07ea1304876ee386b0f29
https://doi.org/10.1182/blood-2020-138391

6

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

المصدر: Blood. 136:50-52

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Bortezomib, business.industry, Immunology, Once weekly, Refractory Multiple Myeloma, Cell Biology, Hematology, Biochemistry, Internal medicine, medicine, business, Dexamethasone, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::c8d1adfc81e4eedd768bc75b4f05040e
https://doi.org/10.1182/blood-2020-137574

7

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

المساهمون: Karyopharm, Mateos M.V., Gavriatopoulou M., Facon T., Auner H.W., Leleu X., Hajek R., Dimopoulos M.A., Delimpasi S., Simonova M., Spicka I., Pour L., Kriachok I., Pylypenko H., Doronin V., Usenko G., Benjamin R., Dolai T.K., Sinha D.K., Venner C.P., Garg M., Stevens D.A., Quach H., Jagannath S., Moreau P., Levy M., Badros A.Z., Anderson L.D., Bahlis N.J., Cavo M., Chai Y., Jeha J., Arazy M., Shah J., Shacham S., Kauffman M.G., Richardson P.G., Grosicki S.

المصدر: Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, medicine.medical_specialty, SINE compound, Selinexor, Dexamethasone, Bortezomib, 03 medical and health sciences, 0302 clinical medicine, Multiple myeloma, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Hydrazine, Humans, Diseases of the blood and blood-forming organs, 1112 Oncology and Carcinogenesis, Adverse effect, Molecular Biology, Letter to the Editor, 1102 Cardiorespiratory Medicine and Haematology, RC254-282, Lenalidomide, Antineoplastic Combined Chemotherapy Protocol, Science & Technology, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Exportin-1, Hematology, Triazoles, medicine.disease, Regimen, 030104 developmental biology, Prior Therapy, Hydrazines, 030220 oncology & carcinogenesis, Proteasome inhibitor, Female, RC633-647.5, business, Life Sciences & Biomedicine, medicine.drug, Human

وصف الملف: STAMPA

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaf7cc61cc2d359ff206c62213e34e08
http://hdl.handle.net/10044/1/89189

8

Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

المساهمون: Auner H.W., Gavriatopoulou M., Delimpasi S., Simonova M., Spicka I., Pour L., Dimopoulos M.A., Kriachok I., Pylypenko H., Leleu X., Doronin V., Usenko G., Hajek R., Benjamin R., Dolai T.K., Sinha D.K., Venner C.P., Garg M., Stevens D.A., Quach H., Jagannath S., Moreau P., Levy M., Badros A., Anderson L.D., Bahlis N.J., Facon T., Mateos M.V., Cavo M., Chai Y., Arazy M., Shah J., Shacham S., Kauffman M.G., Richardson P.G., Grosicki S.

مصطلحات موضوعية: Oncology, Male, Gastrointestinal Diseases, Kaplan-Meier Estimate, Severity of Illness Index, Dexamethasone, Bortezomib, 0302 clinical medicine, Retrospective Studie, Antineoplastic Combined Chemotherapy Protocols, Hydrazine, Multicenter Studies as Topic, Age Factor, Multiple myeloma, Randomized Controlled Trials as Topic, Aged, 80 and over, Frailty, Age Factors, Peripheral Nervous System Diseases, Hematology, Middle Aged, Progression-Free Survival, Hydrazines, Tolerability, 030220 oncology & carcinogenesis, Female, Multiple Myeloma, medicine.drug, Human, Adult, medicine.medical_specialty, Gastrointestinal Disease, Subgroup analysis, Drug Administration Schedule, 03 medical and health sciences, Internal medicine, Severity of illness, medicine, Humans, Progression-free survival, Lenalidomide, Retrospective Studies, Aged, Antineoplastic Combined Chemotherapy Protocol, business.industry, Hematologic Disease, Triazoles, medicine.disease, Hematologic Diseases, Clinical Trials, Phase III as Topic, Peripheral Nervous System Disease, business, 030215 immunology

وصف الملف: STAMPA

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98a9cd6d43172e2122cda2b0568bd327
https://hdl.handle.net/11585/865006

9

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

المؤلفون: Vesselina Goranova-Marinova, Eirini Katodritou, Mamta Garg, Michael G. Kauffman, Paul G. Richardson, Lingling Li, Monica Galli, Sosana Delimpasi, Sebastian Grosicki, Jelena Bila, Galina Salogub, Dinesh Kumar Sinha, Holger W. Auner, Larry D. Anderson, Sybiryna Korenkova, Don A. Stevens, Melina Arazy, Reuben Benjamin, Supratik Basu, Jacqueline Jeha, Moshe Yair Levy, Artur Jurczyszyn, Nizar J. Bahlis, Jean Richard Saint-Martin, Jatin P. Shah, Hang Quach, Anna M. Liberati, Tuphan Kanti Dolai, Iryrna Kriachok, Roman Hájek, Anita A. Joshi, Darrell White, Michele Cavo, Sundar Jagannath, Meletios A. Dimopoulos, Xavier Leleu, Hanna Oliynyk, Pawel Robak, Maryana Simonova, Ganna Usenko, Ludek Pour, Maria V. Mateos, Ivan Spicka, Moshe E. Gatt, Atanas Radinoff, Craig T. Wallington-Beddoe, Jeevan Kumar, Vishnuvardhan Peddagali, Halyna Pylypenko, Thierry Facon, Christopher P. Venner, Donna E. Reece, Sharon Shacham, Maria Gavriatopoulou, Yi Chai, Mercedes Gironella, Vadim A Doronin, P. Moreau

المساهمون: Karyopharm, Grosicki S., Simonova M., Spicka I., Pour L., Kriachok I., Gavriatopoulou M., Pylypenko H., Auner H.W., Leleu X., Doronin V., Usenko G., Bahlis N.J., Hajek R., Benjamin R., Dolai T.K., Sinha D.K., Venner C.P., Garg M., Gironella M., Jurczyszyn A., Robak P., Galli M., Wallington-Beddoe C., Radinoff A., Salogub G., Stevens D.A., Basu S., Liberati A.M., Quach H., Goranova-Marinova V.S., Bila J., Katodritou E., Oliynyk H., Korenkova S., Kumar J., Jagannath S., Moreau P., Levy M., White D., Gatt M.E., Facon T., Mateos M.V., Cavo M., Reece D., Anderson L.D., Saint-Martin J.-R., Jeha J., Joshi A.A., Chai Y., Li L., Peddagali V., Arazy M., Shah J., Shacham S., Kauffman M.G., Dimopoulos M.A., Richardson P.G., Delimpasi S.

المصدر: Lancet (London, England). 396(10262)

مصطلحات موضوعية: Male, medicine.medical_treatment, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Gastroenterology, Dexamethasone, multiple myeloma, Selinexor, dexamethasone, Bortezomib, 0302 clinical medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, 030212 general & internal medicine, Multiple myeloma, 11 Medical and Health Sciences, education.field_of_study, General Medicine, Middle Aged, Progression-Free Survival, Hydrazines, XPO1, Female, Multiple Myeloma, Life Sciences & Biomedicine, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Population, Antineoplastic Agents, Drug Administration Schedule, 03 medical and health sciences, Medicine, General & Internal, Internal medicine, General & Internal Medicine, medicine, Humans, Progression-free survival, education, Aged, Chemotherapy, Science & Technology, business.industry, Triazoles, medicine.disease, EFFICACY, Regimen, Proteasome inhibitor, business, PERIPHERAL NEUROPATHY

وصف الملف: STAMPA

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e64360017cbcc0f8fe4ee44615eeefcf
https://pubmed.ncbi.nlm.nih.gov/33933202

View record from ScienceDirect

Find this article in full text from ProQuest

Full Text via ClinicalKey

10

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

المؤلفون: Ying Yuan, Mikkael A. Sekeres, Douglas V. Faller, Suman Kambhampati, Eduardo Ciliao Munhoz, Vadim A Doronin, Raquel de Paz Arias, María Díez-Campelo, Larisa Girshova, Lionel Ades, Nora-Athina Viniou, David Valcárcel, Achilles Anagnostopoulos, Argiris Symeonidis, Robert J. Fram, Dariusz Woszczyk, Valeria Santini, Uwe Platzbecker

المصدر: Blood. 138:242-242

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Myelodysplastic syndromes, Immunology, Azacitidine, Chronic myelomonocytic leukemia, Myeloid leukemia, Cell Biology, Hematology, medicine.disease, Biochemistry, First line treatment, Internal medicine, medicine, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::1da872f6a4aa86dd54c461344e71f90c
https://doi.org/10.1182/blood-2021-146154

تنقيح النتائج